Investor FAQs

Show all

Aeglea BioTherapeutics is headquartered at 901 South Mo Pac Expressway Ste. 250, Barton Oaks Plaza One, Austin, TX 78746.
Aeglea BioTherapeutics is incorporated in the state of Delaware.
Aeglea BioTherapeutics will end the fiscal year on December 31st.
Aeglea BioTherapeutics trades on the NASDAQ Global Market under the symbol “AGLE”.
Aeglea BioTherapeutics’ transfer agent is American Stock Transfer & Trust Company, LLC.
American Stock Transfer & Trust Company
(800) 937-5449 (Toll-free)
(718) 921-8124 (International)
http://www.amstock.com/new/InvestorServices/ShareholderServices.aspx

If delivering by mail:

American Stock Transfer & Trust Company Operations Center
Attn: Reorganization Department
P.O. Box 2042
New York, NY 10272-2042

If delivering by hand or courier:

American Stock Transfer & Trust Company
Operations Center
Attn: Reorganization Department
6201 15th Avenue
Brooklyn, NY 11219
Aeglea BioTherapeutics’s auditor is PricewaterhouseCoopers LLP, Austin, Texas.
Aeglea BioTherapeutics SEC filings can be viewed on our SEC Filings page.
You can submit queries to Aeglea BioTherapeutics investor relations department by contacting investors@aegleabio.com.